Dallas, TX (PRWEB) October 29, 2009
The Mulligan Law Firm is a national law firm located in Dallas, Texas, providing information and resources for injured individuals and their families in all 50 states. The firm has successfully resolved over $600,000,000 in claims for its clients since 1995.
The Mulligan Law Firm is currently investigating injury claims involving the Calaxo bone screw. Any individual who has been seriously injured after being implanted with this device should consult with a legal professional immediately.
Contact Eric Gruenwald, Lawyer/Attorney or Attorney/Lawyer at (866) 529-0001, Ext. 245. The Mulligan Law Firm takes all cases on a contingency-fee basis, which means the prospective client does not pay for their services unless an award or compensation is received.
The Calaxo bone screw first began to be used after FDA approval in 2006. Almost immediately, reports from the US Food and Drug Administration began to surface about possible severe side effects. In some cases, patients were developing soft-tissue swelling between two and 36 weeks after surgery. The screws were breaking inside the body and causing severe knee pain.
There were reports of painful swelling, infection, fluid buildup, and additional surgeries needed to remove broken screw fragments and infected tissue and bone. In a few cases, surgeons also replaced the fragmented polymer screw with an alternate screw or bone graft.
Injuries to the ACL ligament are the most common type of knee injury, suffered by athletes, weekend athletes, and persons who take a sudden fall.
From March 2006 to August 2007, treatments for this common knee injury typically involved reconstructive surgery and implantation of the Calaxo bone screw.
About the Calaxo Screw
Manufactured by Smith & Nephew, the Calaxo screw (officially known as the Calaxo Osteoconductive Interference Screw) was approved by the FDA and first made available for use in the U.S. in March of 2006.
Developed to replace the metal screws in use at that time, the Calaxo screw is composed of bioabsorbable polymer and calcium carbonate. The metal screws required a follow-up operation to remove, but the Calaxo screw was designed to stay in the body and be absorbed over the 12 month period following surgery. The Calaxo screw tethered the ligament, and as it dissolved it was supposed to promote bone growth and increase the speed of healing.
In August of 2007, Smith & Nephew issued a voluntary recall of all lots of the Calaxo screw, in light of increasing reports of severe surgical side effects. According to the FDA, over 68,000 units were recalled in the U.S.